In this issue
After growing reports of misuse and harm, including increased implication in drug-related deaths, the Advisory Council on the Misuse of Drugs recommended that tramadol should be reclassified as a class C, Schedule 3 drug. This was enacted in June 2014.
The Yellow Card Scheme is vital in helping the Medicines and Healthcare products Regulatory Agency (MHRA) monitor the safety of medicines and vaccines that are on the market. The Yellow Card Centre Wales (YCC Wales) is one of five regional adverse drug reaction (ADR) monitoring centres acting on behalf of the MHRA.
How different types of tic disorders are diagnosed and the appropriate therapeutic options for their management, with a focus on Tourette syndrome.
Primary prevention of cardiovascular disease with statins: assessing the evidence base behind clinical guidanceSubscription
Statins and other cholesterol-lowering drugs are increasingly being used for primary prevention of atherosclerotic cardiovascular disease. Three lines of evidence inform the development of therapeutic goals for both drug and lifestyle intervention. This evidence reveals the following principles for cholesterol lowering in primary prevention: (a) ‘the more (lowering), the better’ for relative risk reduction, (b) ‘the lower, the better’ for absolute risk reduction, and (c) ‘the earlier, ...
Considerations in selecting pharmacological treatments for attention deficit hyperactivity disorder Subscription
Attention deficit hyperactivity disorder (ADHD) is highly prevalent and is associated with significant impairment across the lifespan. Medication treatments, particularly stimulant medications, are important in the management of ADHD, although non-medication treatments (e.g. therapy to improve organisational, social and emotional regulation skills) are often also needed. The stimulant medications have a high response rate and improve the core symptoms of the disorder, but they are ...